{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T13:31:56Z","timestamp":1793971916848,"version":"4.8.0"},"reference-count":39,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2019,10,21]],"date-time":"2019-10-21T00:00:00Z","timestamp":1571616000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Cancer Institute\/National Institutes of Health","award":["CRADA between NCI and EMD Serono"],"award-info":[{"award-number":["CRADA between NCI and EMD Serono"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["j. immunotherapy cancer"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s40425-019-0723-9","type":"journal-article","created":{"date-parts":[[2019,10,21]],"date-time":"2019-10-21T16:20:27Z","timestamp":1571674827000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":120,"title":["Efficacy and tolerability of anti-programmed death-ligand 1 (PD-L1) antibody (Avelumab) treatment in advanced thymoma"],"prefix":"10.1136","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2776-3385","authenticated-orcid":false,"given":"Arun","family":"Rajan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher R.","family":"Heery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anish","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew L.","family":"Mammen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Perry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geraldine","family":"O\u2019Sullivan Coyne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Udayan","family":"Guha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arlene","family":"Berman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Szabo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi A.","family":"Madan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leomar Y.","family":"Ballester","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Pittaluga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renee N.","family":"Donahue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yo-Ting","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren M.","family":"Lepone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Chin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona","family":"Ginty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anup","family":"Sood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen M.","family":"Hewitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Schlom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffit","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James L.","family":"Gulley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2019,10,21]]},"reference":[{"issue":"1","key":"723_CR1","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.ejcts.2009.05.038","volume":"37","author":"F Venuta","year":"2010","unstructured":"Venuta F, Anile M, Diso D, Vitolo D, Rendina EA, De Giacomo T, et al. Thymoma and thymic carcinoma. Eur J Cardiothorac Surg. 2010;37(1):13\u201325.","journal-title":"Eur J Cardiothorac Surg"},{"issue":"5","key":"723_CR2","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1586\/era.12.29","volume":"12","author":"N Girard","year":"2012","unstructured":"Girard N. Chemotherapy and targeted agents for thymic malignancies. Expert Rev Anticancer Ther. 2012;12(5):685\u201395.","journal-title":"Expert Rev Anticancer Ther"},{"issue":"3","key":"723_CR3","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1038\/cmi.2010.74","volume":"8","author":"S Shelly","year":"2011","unstructured":"Shelly S, Agmon-Levin N, Altman A, Shoenfeld Y. Thymoma and autoimmunity. Cell Mol Immunol. 2011;8(3):199\u2013202.","journal-title":"Cell Mol Immunol"},{"issue":"7","key":"723_CR4","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1084\/jem.192.7.1027","volume":"192","author":"GJ Freeman","year":"2000","unstructured":"Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med. 2000;192(7):1027\u201334.","journal-title":"J Exp Med"},{"issue":"4","key":"723_CR5","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","volume":"12","author":"DM Pardoll","year":"2012","unstructured":"Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252\u201364.","journal-title":"Nat Rev Cancer"},{"issue":"17","key":"723_CR6","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.1200\/JCO.2014.59.4358","volume":"33","author":"MA Postow","year":"2015","unstructured":"Postow MA, Callahan MK, Wolchok JD. Immune checkpoint blockade in Cancer therapy. J Clin Oncol. 2015;33(17):1974\u201382.","journal-title":"J Clin Oncol"},{"key":"723_CR7","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.coi.2015.01.006","volume":"33","author":"DS Shin","year":"2015","unstructured":"Shin DS, Ribas A. The evolution of checkpoint blockade as a cancer therapy: what's here, what's next? Curr Opin Immunol. 2015;33:23\u201335.","journal-title":"Curr Opin Immunol"},{"key":"723_CR8","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.coi.2015.12.001","volume":"39","author":"M Vormehr","year":"2016","unstructured":"Vormehr M, Diken M, Boegel S, Kreiter S, Tureci O, Sahin U. Mutanome directed cancer immunotherapy. Curr Opin Immunol. 2016;39:14\u201322.","journal-title":"Curr Opin Immunol"},{"issue":"6280","key":"723_CR9","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1126\/science.aaf1490","volume":"351","author":"N McGranahan","year":"2016","unstructured":"McGranahan N, Furness AJ, Rosenthal R, Ramskov S, Lyngaa R, Saini SK, et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science. 2016;351(6280):1463\u20139.","journal-title":"Science."},{"issue":"19","key":"723_CR10","doi-asserted-by":"publisher","first-page":"5064","DOI":"10.1158\/1078-0432.CCR-13-3271","volume":"20","author":"JM Taube","year":"2014","unstructured":"Taube JM, Klein A, Brahmer JR, Xu H, Pan X, Kim JH, et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res. 2014;20(19):5064\u201374.","journal-title":"Clin Cancer Res"},{"key":"723_CR11","doi-asserted-by":"publisher","first-page":"7336","DOI":"10.1038\/srep07336","volume":"4","author":"Y Wang","year":"2014","unstructured":"Wang Y, Thomas A, Lau C, Rajan A, Zhu Y, Killian JK, et al. Mutations of epigenetic regulatory genes are common in thymic carcinomas. Sci Rep. 2014;4:7336.","journal-title":"Sci Rep"},{"issue":"2","key":"723_CR12","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.ccell.2018.01.003","volume":"33","author":"M Radovich","year":"2018","unstructured":"Radovich M, Pickering CR, Felau I, Ha G, Zhang H, Jo H, et al. The integrated genomic landscape of Thymic epithelial tumors. Cancer Cell. 2018;33(2):244\u201358 e10.","journal-title":"Cancer Cell"},{"issue":"3","key":"723_CR13","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1097\/JTO.0000000000000429","volume":"10","author":"SK Padda","year":"2015","unstructured":"Padda SK, Riess JW, Schwartz EJ, Tian L, Kohrt HE, Neal JW, et al. Diffuse high intensity PD-L1 staining in thymic epithelial tumors. J Thorac Oncol. 2015;10(3):500\u20138.","journal-title":"J Thorac Oncol"},{"issue":"2","key":"723_CR14","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.lungcan.2015.03.003","volume":"88","author":"Y Katsuya","year":"2015","unstructured":"Katsuya Y, Fujita Y, Horinouchi H, Ohe Y, Watanabe S, Tsuta K. Immunohistochemical status of PD-L1 in thymoma and thymic carcinoma. Lung Cancer. 2015;88(2):154\u20139.","journal-title":"Lung Cancer"},{"issue":"4","key":"723_CR15","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1016\/j.athoracsur.2015.10.044","volume":"101","author":"S Yokoyama","year":"2016","unstructured":"Yokoyama S, Miyoshi H, Nishi T, Hashiguchi T, Mitsuoka M, Takamori S, et al. Clinicopathologic and prognostic implications of programmed death ligand 1 expression in Thymoma. Ann Thorac Surg. 2016;101(4):1361\u20139.","journal-title":"Ann Thorac Surg"},{"key":"723_CR16","unstructured":"NCT01772004. \n                    Clinicaltrials.gov\n                    \n                   (online). \n                    https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01772004?term=NCT01772004&rank=1\n                    \n                  . Accessed on December 14, 2018."},{"issue":"5","key":"723_CR17","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/S1470-2045(17)30239-5","volume":"18","author":"CR Heery","year":"2017","unstructured":"Heery CR, O'Sullivan-Coyne G, Madan RA, Cordes L, Rajan A, Rauckhorst M, et al. Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN solid tumor): a phase 1a, multicohort, dose-escalation trial. Lancet Oncol. 2017;18(5):587\u201398.","journal-title":"Lancet Oncol."},{"issue":"29","key":"723_CR18","doi-asserted-by":"publisher","first-page":"11982","DOI":"10.1073\/pnas.1300136110","volume":"110","author":"MJ Gerdes","year":"2013","unstructured":"Gerdes MJ, Sevinsky CJ, Sood A, Adak S, Bello MO, Bordwell A, et al. Highly multiplexed single-cell analysis of formalin-fixed, paraffin-embedded cancer tissue. Proc Natl Acad Sci U S A. 2013;110(29):11982\u20137.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"723_CR19","first-page":"1","volume":"5","author":"LM Lepone","year":"2016","unstructured":"Lepone LM, Donahue RN, Grenga I, Metenou S, Richards J, Heery CR, et al. Analysis of 123 peripheral human immune cell subsets: defining differences with age and between healthy donors and cancer patients not detected in analysis of standard immune cell types. J Circ Biomark. 2016;5(5):1\u201317.","journal-title":"J Circ Biomark"},{"key":"723_CR20","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s40425-017-0220-y","volume":"5","author":"RN Donahue","year":"2017","unstructured":"Donahue RN, Lepone LM, Grenga I, Jochems C, Fantini M, Madan RA, et al. Analyses of the peripheral immunome following multiple administrations of avelumab, a human IgG1 anti-PD-L1 monoclonal antibody. J Immunother Cancer. 2017;5:20.","journal-title":"J Immunother Cancer"},{"issue":"1","key":"723_CR21","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1136\/annrheumdis-2018-213777","volume":"78","author":"AL Mammen","year":"2019","unstructured":"Mammen AL, Rajan A, Pak K, Lehky T, Casciola-Rosen L, Donahue RN, et al. Pre-existing antiacetylcholine receptor autoantibodies and B cell lymphopaenia are associated with the development of myositis in patients with thymoma treated with avelumab, an immune checkpoint inhibitor targeting programmed death-ligand 1. Ann Rheum Dis. 2019;78(1):150\u20132.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"723_CR22","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/S1470-2045(18)30062-7","volume":"19","author":"G Giaccone","year":"2018","unstructured":"Giaccone G, Kim C, Thompson J, McGuire C, Kallakury B, Chahine JJ, et al. Pembrolizumab in patients with thymic carcinoma: a single-arm, single-Centre, phase 2 study. Lancet Oncol. 2018;19(3):347\u201355.","journal-title":"Lancet Oncol."},{"issue":"24","key":"723_CR23","doi-asserted-by":"publisher","first-page":"2162","DOI":"10.1200\/JCO.2017.77.3184","volume":"37","author":"Jinhyun Cho","year":"2019","unstructured":"Cho J, Kim HS, Ku BM, Choi YL, Cristescu R, Han J, et al. Pembrolizumab for patients with refractory or relapsed thymic epithelial tumor: an open-label phase II trial. J Clin Oncol. 2019;37(24):2162\u201370.","journal-title":"Journal of Clinical Oncology"},{"key":"723_CR24","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.ejca.2015.11.016","volume":"54","author":"JM Michot","year":"2016","unstructured":"Michot JM, Bigenwald C, Champiat S, Collins M, Carbonnel F, Postel-Vinay S, et al. Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer. 2016;54:139\u201348.","journal-title":"Eur J Cancer"},{"key":"723_CR25","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.ejca.2016.02.024","volume":"60","author":"L Zimmer","year":"2016","unstructured":"Zimmer L, Goldinger SM, Hofmann L, Loquai C, Ugurel S, Thomas I, et al. Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy. Eur J Cancer. 2016;60:210\u201325.","journal-title":"Eur J Cancer"},{"issue":"10","key":"723_CR26","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1016\/S1470-2045(16)30364-3","volume":"17","author":"HL Kaufman","year":"2016","unstructured":"Kaufman HL, Russell J, Hamid O, Bhatia S, Terheyden P, D'Angelo SP, et al. Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial. Lancet Oncol. 2016;17(10):1374\u201385.","journal-title":"Lancet Oncol."},{"issue":"5","key":"723_CR27","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/S1470-2045(17)30240-1","volume":"18","author":"JL Gulley","year":"2017","unstructured":"Gulley JL, Rajan A, Spigel DR, Iannotti N, Chandler J, Wong DJ, et al. Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN solid tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial. Lancet Oncol. 2017;18(5):599\u2013610.","journal-title":"Lancet Oncol."},{"issue":"10","key":"723_CR28","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1158\/2326-6066.CIR-15-0059","volume":"3","author":"B Boyerinas","year":"2015","unstructured":"Boyerinas B, Jochems C, Fantini M, Heery CR, Gulley JL, Tsang KY, et al. Antibody-dependent cellular cytotoxicity activity of a novel anti-PD-L1 antibody avelumab (MSB0010718C) on human tumor cells. Cancer Immunol Res. 2015;3(10):1148\u201357.","journal-title":"Cancer Immunol Res"},{"issue":"6","key":"723_CR29","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.it.2012.03.005","volume":"33","author":"G Anderson","year":"2012","unstructured":"Anderson G, Takahama Y. Thymic epithelial cells: working class heroes for T cell development and repertoire selection. Trends Immunol. 2012;33(6):256\u201363.","journal-title":"Trends Immunol"},{"issue":"111","key":"723_CR30","doi-asserted-by":"publisher","first-page":"111ra20","DOI":"10.1126\/scitranslmed.3003130","volume":"3","author":"S Amarnath","year":"2011","unstructured":"Amarnath S, Mangus CW, Wang JC, Wei F, He A, Kapoor V, et al. The PDL1-PD1 axis converts human TH1 cells into regulatory T cells. Sci Transl Med. 2011;3(111):111ra20.","journal-title":"Sci Transl Med"},{"issue":"2","key":"723_CR31","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/S1470-2045(14)71181-7","volume":"16","author":"A Thomas","year":"2015","unstructured":"Thomas A, Rajan A, Berman A, Tomita Y, Brzezniak C, Lee MJ, et al. Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial. Lancet Oncol. 2015;16(2):177\u201386.","journal-title":"Lancet Oncol"},{"issue":"20","key":"723_CR32","doi-asserted-by":"publisher","first-page":"6674","DOI":"10.1158\/1078-0432.CCR-07-5212","volume":"14","author":"JH Finke","year":"2008","unstructured":"Finke JH, Rini B, Ireland J, Rayman P, Richmond A, Golshayan A, et al. Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients. Clin Cancer Res. 2008;14(20):6674\u201382.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"723_CR33","doi-asserted-by":"publisher","first-page":"2514","DOI":"10.1158\/0008-5472.CAN-08-4709","volume":"69","author":"J Ozao-Choy","year":"2009","unstructured":"Ozao-Choy J, Ma G, Kao J, Wang GX, Meseck M, Sung M, et al. The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies. Cancer Res. 2009;69(6):2514\u201322.","journal-title":"Cancer Res"},{"issue":"8","key":"723_CR34","doi-asserted-by":"publisher","first-page":"1948","DOI":"10.1002\/ijc.26219","volume":"130","author":"B Farsaci","year":"2012","unstructured":"Farsaci B, Higgins JP, Hodge JW. Consequence of dose scheduling of sunitinib on host immune response elements and vaccine combination therapy. Int J Cancer. 2012;130(8):1948\u201359.","journal-title":"Int J Cancer"},{"issue":"3","key":"723_CR35","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/nri3155","volume":"12","author":"CS Hsieh","year":"2012","unstructured":"Hsieh CS, Lee HM, Lio CW. Selection of regulatory T cells in the thymus. Nat Rev Immunol. 2012;12(3):157\u201367.","journal-title":"Nat Rev Immunol"},{"key":"723_CR36","unstructured":"NCT03076554. \n                    Clinicaltrials.gov\n                    \n                   (online). \n                    https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03076554?term=NCT03076554&rank=1\n                    \n                  . Accessed on December 14."},{"issue":"6","key":"723_CR37","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1158\/0008-5472.CAN-16-2324","volume":"77","author":"DY Oh","year":"2017","unstructured":"Oh DY, Cham J, Zhang L, Fong G, Kwek SS, Klinger M, et al. Immune toxicities elicted by CTLA-4 blockade in cancer patients are associated with early diversification of the T-cell repertoire. Cancer Res. 2017;77(6):1322\u201330.","journal-title":"Cancer Res"},{"issue":"2","key":"723_CR38","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1172\/JCI96798","volume":"128","author":"R Das","year":"2018","unstructured":"Das R, Bar N, Ferreira M, Newman AM, Zhang L, Bailur JK, et al. Early B cell changes predict autoimmunity following combination immune checkpoint blockade. J Clin Invest. 2018;128(2):715\u201320.","journal-title":"J Clin Invest"},{"issue":"7","key":"723_CR39","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1007\/s00262-014-1545-8","volume":"63","author":"E Simeone","year":"2014","unstructured":"Simeone E, Gentilcore G, Giannarelli D, Grimaldi AM, Caraco C, Curvietto M, et al. Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma. Cancer Immunol Immunother. 2014;63(7):675\u201383.","journal-title":"Cancer Immunol Immunother"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40425-019-0723-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s40425-019-0723-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40425-019-0723-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T17:45:26Z","timestamp":1601055926000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1186\/s40425-019-0723-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,21]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["723"],"URL":"https:\/\/doi.org\/10.1186\/s40425-019-0723-9","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,21]]},"assertion":[{"value":"16 May 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All patients provided written informed consent for participation in a clinical trial that was approved by the Institutional Review Board at the National Cancer Institute (ClinicalTrials ID: NCT01772004; NCI Clinical Trial ID: 13-C-0063).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable (individual details with identifiers not presented).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"A.R. \u2013 None, other than the CRADA mentioned in the <i>Funding<\/i> section.C.R.H. \u2013 None, other than the CRADA mentioned in the <i>Funding<\/i> section.A.T. \u2013 None.A.L.M. \u2013 None.S.Pe. \u2013 None.G.O.S.C. \u2013 None.U.G. \u2013 None.A.B. \u2013 None.E.S. \u2013 None.R.A.M. \u2013 None.L.Y.B. \u2013 None.S.Pi. \u2013 None.R.N.D. \u2013 None.Y-T.T. - None.L.M.L. \u2013 None.K.C. \u2013 Dr. Chin discloses that he is an employee of EMD Serono.F.G. \u2013 Dr. Ginty reports that her employer, GE Global Research Corporation and its parent company, GE, is the developer of the Cell-DIVE multiplex in situ immunofluorescence analysis platform used for a portion of this study.A.S. \u2013 Dr. Sood reports that his employer, GE Global Research Corporation and its parent company, GE, is the developer of the Cell-DIVE multiplex in situ immunofluorescence analysis platform used for a portion of this study.S.M.H. \u2013 None.J.S. \u2013 None, other than the CRADA mentioned in the <i>Funding<\/i> section.R.H. \u2013 None.J.L.G. \u2013 None, other than the CRADA mentioned in the <i>Funding<\/i> section.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"269"}}